The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Updated safety and efficacy data from the phase 3 MANIFEST-2 study of pelabresib in combination with ruxolitinib for JAK inhibitor treatment-naïve patients with myelofibrosis.
 
Raajit Rampal
Honoraria - Protagonist Therapeutics
Consulting or Advisory Role - Abbvie; Blueprint Medicines; Bristol-Myers Squibb/Celgene; Constellation Pharmaceuticals; CTI BioPharma Corp; Disc Medicine; Galecto; Incyte; Karyopharm Therapeutics; Novartis; Pharmaessentia; Promedior; SERVIER; Sierra Oncology; Stemline Therapeutics; Sunimoto Dainippon; Zentalis
Research Funding - Constellation Pharmaceuticals; Ryvu Therapeutics; Stemline Therapeutics; Zentalis
Travel, Accommodations, Expenses - Incyte; Sierra Oncology
 
Sebastian Grosicki
No Relationships to Disclose
 
Dominik Chraniuk
Consulting or Advisory Role - Janssen
 
Elisabetta Abruzzese
Consulting or Advisory Role - Ascentage Pharma; Bristol-Myers Squibb; Incyte; MorphoSys; Novartis; Pfizer
 
Prithviraj Bose
Honoraria - Abbvie; Blueprint Medicines; BMS; Cogent Biosciences; CTI BioPharma Corp; GlaxoSmithKline; Incyte; Ionis Pharmaceuticals; Jubilant Therapeutics; Karyopharm Therapeutics; Morphic Therapeutic; MorphoSys; Novartis; Pharmaessentia
Consulting or Advisory Role - Ono Pharmaceutical; Sierra Oncology
Research Funding - Blueprint Medicines (Inst); Bristol Myers Squibb (Inst); Celgene (Inst); Celgene (Inst); Cogent Biosciences (Inst); Constellation Pharmaceuticals (Inst); CTI BioPharma Corp (Inst); Geron (Inst); Incyte (Inst); Ionis Pharmaceuticals (Inst); Janssen (Inst); Kartos Therapeutics (Inst); Karyopharm Therapeutics (Inst); MorphoSys (Inst); Telios (Inst)
 
Aaron Thomas Gerds
Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb/Celgene; CTI; GlaxoSmithKline/Sierra Oncology; Imago Pharma; Kartos Therapeutics; MorphoSys; Pharmaessentia; Rain Therapeutics
Research Funding - Celgene; CTI; Gilead Sciences; Incyte; Pfizer; Roche/Genentech
 
Alessandro M. Vannucchi
Consulting or Advisory Role - AOP Orphan Pharmaceuticals; Blueprint Medicines; Bristol-Myers Squibb; GlaxoSmithKline; Incyte; Novartis
Speakers' Bureau - AOP Orphan Pharmaceuticals; Blueprint Medicines; BMS GmbH & Co. KG; GlaxoSmithKline; Incyte; Novartis
 
Francesca Palandri
Honoraria - Abbvie; Amgen; AOP Orphan Pharmaceuticals; Celgene; Celgene/Bristol-Myers Squibb; CTI; GlaxoSmithKline; Grifols; Karyopharm Therapeutics; MorphoSys; Novartis; Sierra Oncology; SOBI
Consulting or Advisory Role - Abbvie; Amgen; AOP Orphan Pharmaceuticals; Celgene; Celgene/Bristol-Myers Squibb; CTI; GlaxoSmithKline; Grifols; Karyopharm Therapeutics; MorphoSys; Novartis; Sierra Oncology; SOBI
 
Sung-Eun Lee
No Relationships to Disclose
 
Vikas Gupta
Stock and Other Ownership Interests - Syndax
Honoraria - Abbvie; Bristol-Myers Squibb/Celgene; CTI biophara; GlaxoSmithKline; Incyte; Novartis; Pfizer
Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb/Celgene; CTI BioPharma Corp; GlaxoSmithKline; Incyte; Novartis
Research Funding - Abbvie (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - Patent on MPN24 a gene signature to predict outcome of Myelofibrosis (Inst)
 
Alessandro Lucchesi
Consulting or Advisory Role - Amgen; AOP Orphan Pharmaceuticals; Grifols; MorphoSys; Novartis; Protagonist Therapeutics; Sanofi; SOBI
Speakers' Bureau - Amgen; BMS GmbH & Co. KG; Grifols; Incyte; Novartis; Pfizer; Sanofi; SOBI
 
Andrew Tucker Kuykendall
Honoraria - Abbvie/Genentech; Blueprint Medicines; BMS; GlaxoSmithKline; Imago Pharma; Incyte; MorphoSys; Pharmaessentia; SOBI
Consulting or Advisory Role - GlaxoSmithKline; GlaxoSmithKline; Karyopharm Therapeutics; MorphoSys; Protagonist Therapeutics
Research Funding - Blueprint Medicines (Inst); Bristol-Myers Squibb/Celgene (Inst); Geron (Inst); GlaxoSmithKline (Inst); Janssen Oncology (Inst); MorphoSys (Inst); Novartis (Inst); Protagonist Therapeutics (Inst)
Travel, Accommodations, Expenses - Abbvie; GlaxoSmithKline; Pharmaessentia
 
Ruben A. Mesa
Consulting or Advisory Role - Constellation Pharmaceuticals; La Jolla Pharma; Novartis; Sierra Oncology
Research Funding - Abbvie (Inst); Celgene (Inst); Constellation Pharmaceuticals (Inst); CTI (Inst); Genentech (Inst); Incyte (Inst); Mays Cancer Center (Inst); NCI (Inst); Promedior (Inst); Samus (Inst)
 
Jean-Jacques Kiladjian
Consulting or Advisory Role - Abbvie; AOP Orphan Pharmaceuticals; BMS; GlaxoSmithKline; Incyte; Novartis; Pharmaessentia
 
Moshe Talpaz
Consulting or Advisory Role - Bristol-Myers Squibb/Celgene; Novartis; SDP Oncology
Research Funding - Arcus Biosciences; Bristol-Myers Squibb/Celgene
Travel, Accommodations, Expenses - Sumitomo Dainippon Pharma Oncology
 
Morgan Harris
Employment - Constellation Pharmaceuticals
Stock and Other Ownership Interests - Constellation Pharmaceuticals
 
Manlei Wu
Employment - MorphoSys
Stock and Other Ownership Interests - MorphoSys
 
Barbara Brown
Employment - Constellation Pharmaceuticals
Stock and Other Ownership Interests - Exelixis; Exelixis (I); Lilly; Lilly (I); Moderna Therapeutics; Moderna Therapeutics (I); MorphoSys; Pfizer; Pfizer (I); Verastem
 
Claire Harrison
Honoraria - Abbvie; CTI BioPharma Corp; Geron; GlaxoSmithKline (Inst); Janssen; Novartis
Consulting or Advisory Role - AOP Orphan Pharmaceuticals; BMS; Constellation Pharmaceuticals; CTI; Galecto; Geron; Incyte; Janssen; Keros Therapeutics; MorphoSys; Novartis; Roche
Speakers' Bureau - Abbvie; Bristol-Myers Squibb; CTI BioPharma Corp; Geron; GlaxoSmithKline; Novartis
Research Funding - Bristol-Myers Squibb (Inst); Constellation Pharmaceuticals (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Novartis
 
John Mascarenhas
Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb/Celgene; Constellation Pharmaceuticals; CTI BioPharma Corp; Galecto; Geron; GlaxoSmithKline; Incyte; Kartos Therapeutics; Karyopharm Therapeutics; Karyopharm Therapeutics; Merck; Novartis; Pharmaessentia; Roche/Genentech; Sierra Oncology; Sumitomo Pharma Oncology
Research Funding - Abbvie (Inst); Celgene/Bristol-Myers Squibb (Inst); CTI BioPharma Corp (Inst); Geron (Inst); Incyte (Inst); Kartos Therapeutics (Inst); Merck (Inst); Novartis (Inst); Pharmaessentia (Inst); Roche/Genentech (Inst)